Figure 10.

Stable overexpression of PFKFB4 phosphatase defective mutant could suppress subcutaneous tumor growth in vivo. (A) The lentiviral construct for driving stable expression of PFKFB4 phosphatase defective mutant, H257A was prepared by site-directed mutagenesis and its identity was confirmed by Sanger sequencing. (B) Western blot analysis for PFKFB4 protein expression in control, PFKFB4 wild-type (WT), and PFKFB4 H257A stable–overexpressing Huh7 cells. (C) Comparison of the growth rates among the control, PFKFB4 WT, and PFKFB4 H257 stable–overexpressing Huh7 cell–derived subcutaneous tumor xenografts. (D) The volume of the dissected tumors among different experimental groups was compared at the end point. (E) The tumor mass and tumor volume of the dissected control, PFKFB4 WT, and PFKFB4 H257A mutant stable–overexpressing Huh7 cell–derived subcutaneous tumor xenografts. ∗P < .05.